Answers are grounded in this paper and cite their sources.
Pilot study investigates daratumumab to reduce circulating antibodies in sensitized heart transplant candidates, highlighting a targeted desensitization strategy.
Preformed anti-human leukocyte antigen (HLA) antibodies can significantly restrict transplant options for highly sensitized patients. Many approaches have been pursued for desensitization, including intravenous immunoglobulin, plasmapheresis, rituximab, bortezomib, and carfilzomib, with overall limited effectiveness and significant side effects.1,2
No takes yet. Share an insight, caveat, or question.
Witteles et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: